NEWS

PRESS RELEASE

Vesalio announces FDA Approval of the NeVa VS™ to treat cerebral vasospa...

Nashville, Tennessee - (Sept 15, 2022) – Vesalio announces FDA HDE approval for commercialization of NeVa VS, indicated for the adjunct treatment of symptomatic cerebral vasospasm (CV) following aneurysmal subarachnoid hemorrhage (aSAH), the major cause of death and disability in this patient population.  This is the first intracranial technology approved for this indication in the U.S.

BREAKING NEWS

PRESS RELEASE

Vesalio announces CE Approval for new NeVa NET™, the first integrated cl...

Nashville, Tennessee - (September 1, 2022) – In further expansion of their high-performance thrombectomy portfolio, Vesalio announced CE approval for commercialization of the new NeVa NET, the first and only thrombectomy device with an integrated clot micro-filtration technology. This one-of-a-kind stent retriever combines the company’s proprietary Drop Zone technology, proven to work on all clot types, with a finely braided micro-filter net element integrated into the closed distal tip of the device.

BREAKING NEWS

BREAKING NEWS